Bioavailability and Pharmaco-therapeutic Potential of Luteolin in Overcoming Alzheimer’s Disease

Author(s): Fahad Ali , Yasir Hasan Siddique* .

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 18 , Issue 5 , 2019

Become EABM
Become Reviewer

Abstract:

Luteolin is a naturally occurring, yellow crystalline flavonoid found in numerous dietary supplements we frequently have in our meals. Studies in last 2 decades have revealed its therapeutic potential to reduce the Alzheimer’s disease (AD) symptoms in various in vitro and in vivo studies. The anti-Alzheimer’s potential of luteolin is attributed to its ability to suppress Aβ as well as tau aggregation or promote their disaggregation, down-regulate the expression of COX-2, NOS, MMP-9, TNF-α, interleukins and chemokines, reduce oxidative stress by scavenging ROS, modulate the activities of transcription factors CREB, cJun, Nrf-1, NF-κB, p38, p53, AP-1 and β-catenine and inhibiting the activities of various protein kinases. In several systems luteolin has been described as potent antioxidant and anti-inflammatory agent. In addition we have also discussed about the bio-availability of the luteolin in the plasma. After being metabolized luteolin persists in plasma as glucuronides and sulphate-conjugates. Human clinical trials indicated no dose limiting toxicity when administered at a dose of 100 mg/day. Improvements in the formulations and drug delivery systems may further enhance the bioavailability and potency of luteolin. The current review describes in detail the data supporting these studies.

Keywords: Luteolin, Alzheimer’s disease, oxidative stress, bioavailability, ROS, Pharmaco-therapeutic.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2019
Page: [352 - 365]
Pages: 14
DOI: 10.2174/1871527318666190319141835
Price: $95

Article Metrics

PDF: 26